AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01825837
Drug: BIA 2-093 900 mg (Part I)
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
Trial: NCT02959476
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive comparator
Trial: NCT00941720
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
Trial: NCT04309526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00190580
Drug: Conventional antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers
Trial: NCT05299567
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo with the same color and size than azithromycin tree days a wek for 6 months
Trial: NCT00171340
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
Trial: NCT02739204
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
Trial: NCT01879332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets for oral administration
Trial: NCT01685658
Drug: Intravenous ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
Trial: NCT01685658
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
Trial: NCT03020784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03990974
Drug: postoperative antimicrobial prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drugs are all common antibiotics used to prevent postoperative infection in each hospital.
Trial: NCT00554723
Drug: NeuroAid matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
Trial: NCT05123781
Drug: Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of the Reference product was administered orally with 240 ml of water
Trial: NCT00688402
Drug: AZD3355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT00627081
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage
Trial: NCT00810888
Drug: recombinant activated factor VII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Trial: NCT00810888
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
Trial: NCT00608595
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
Trial: NCT02492841
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
Trial: NCT02492841
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
Trial: NCT01886560
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
Trial: NCT01353846
Drug: Agonist GnRH; estradiol Valerate; progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
Trial: NCT00755378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02096588
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
Trial: NCT00690482
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, twice daily
Trial: NCT00690482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral tablet, twice daily
Trial: NCT01930175
Drug: VAY736
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01930175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03508869
Drug: Mirvaso® (brimonidine) topical gel, 0.33%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
Trial: NCT03508869
Drug: Dysport®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
Trial: NCT03508869
Drug: Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
Trial: NCT02549846
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
Trial: NCT01886560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets placebo one PO per day for 12 weeks
Trial: NCT00240617
Drug: sumatriptan succinate/naproxen sodium
RxNorm normalized name: sumatriptan succinate/naproxen sodium 10 mg-60 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator
Trial: NCT00240617
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match
Trial: NCT03199313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Sutezolid placebo
Trial: NCT01660022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01660022
Drug: 300 mg OZ439 single oral dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg OZ439 oral suspension single dose
Trial: NCT01660022
Drug: 800 mg OZ439 single oral dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800mg OZ439 oral suspension single dose
Trial: NCT01380249
Drug: PDM08
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
Trial: NCT03630094
Drug: FEP-ZID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
Trial: NCT00141141
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03695055
Drug: Maintenance therapy post-HSCT
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab vs DPP/DCEP-G vs observation
Trial: NCT00500890
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 g/m\^2 by vein, Over 1 Hour x 2 Days
Trial: NCT00922324
Drug: STP206 or vehicle control
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
Trial: NCT04184999
Drug: Prednisolone Acetate 1% Oph Susp
RxNorm normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical ophthalmic steroid drop
Trial: NCT00280176
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 225mg/m2 given weekly, up to 6 weeks
Trial: NCT03020719
Drug: Oral Glutathione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glutathione oral powder
Trial: NCT03020719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral powder
Trial: NCT04509999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as formulated by mouth daily
Trial: NCT02870036
Drug: Simmitecan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02870036
Drug: 5-fluorouracil and Leucovorin Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02521181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
Trial: NCT01297816
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg,BD, fo three month
Trial: NCT01297816
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg
Trial: NCT02459418
Drug: Afolia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
Trial: NCT00109837
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide Consolidation: 650 mg/m2; IV; days 1, 15, 29 Post-consolidation course 3: 650 mg/m2; IV; day 1
Trial: NCT00109837
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post consolidation: 25 mg/m2; IV; days 1, 8, 15, and 22
Trial: NCT00109837
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For CNS during induction: 5 mg every 6 hrs for 4 doses; PO; days 1, 4, 8, 11, etx.; after methotrexate if WBC \< 3,000
Trial: NCT00109837
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consolidation: 60 mg/m2; PO; days 1-28 Post-consolidation course 1: 60 mg/m2/d; PO; days 1-63 Post-consolidation course 4: 60 mg/m2/d; PO; daily for 2 yrs
Trial: NCT00109837
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation: 12 mg; intrathecal or intraventricularly; days 2, 9, 16, and 23 Post-consolidation course 1: 20 mg/m2/wk; PO; days 1, 8 15, 22, 29, 36, 43, 50, 57 Post-consolidation course 4: 20 mg/m2; PO; weekly for 2 yrs
Trial: NCT00836147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
Trial: NCT00982501
Drug: WS® 1442 900 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00982501
Drug: WS® 1442 1800 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00955552
Drug: Glucosamine sulphate and chondroitin sulphate association
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal
Trial: NCT00955552
Drug: Cosamin DS® (Nutramax)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule of glucosamine hydrochloride 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days
Trial: NCT00128466
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00128466
Drug: streptomycin
RxNorm normalized name: Streptomycin
DrugBank: Streptomycin (DB01082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00614926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
Trial: NCT01188265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPA plus placebo
Trial: NCT01518595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pts. will receive placebo for 3 months
Trial: NCT01529307
Drug: TAS266
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS266 IV infusions given weekly
Trial: NCT00491907
Drug: folic acid 5mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00317642
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (sodium Chloride) 1-hour IV infusion
Trial: NCT01546142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline placebo for injection
Trial: NCT02975037
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarithromycin 250 mg PO
Trial: NCT00556491
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses
Trial: NCT00556491
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
Trial: NCT00809965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet twice daily
Trial: NCT00809965
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03580564
Drug: KL-A167
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
Trial: NCT00882206
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 5, 60 mg/m\^2 intravenously (IV) over 15 minutes
Trial: NCT00882206
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: \*\*Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
Trial: NCT00705120
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01826461
Drug: PDI-192
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01826461
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00505648
Drug: Tegeline®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.
Trial: NCT01164215
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
Trial: NCT01164215
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
Trial: NCT01028911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.~Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
Trial: NCT00284804
Drug: MDX-060
RxNorm normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
Trial: NCT01077817
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02593396
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
Trial: NCT04344457
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg PO TID 14 Days
Trial: NCT04344457
Drug: Zithromax Oral Product
RxNorm normalized name: Zithromax Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg PO QD 3 Days
Trial: NCT04273282
Drug: Prednisolone Acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.
Trial: NCT00368563
Drug: Helioblock SX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005086
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01010750
Drug: LDX Placebo + MAS-IR Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
Trial: NCT00667004
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT02573857
Drug: DSM265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension from bulk powder
Trial: NCT01652976
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
Trial: NCT00295685
Drug: Antacids
RxNorm normalized name: ANTACIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02726646
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of 1 mg of doxyxycline microspheres at 4 sites (two means and two deep periodontal pockets) after mechanical debridement.
Trial: NCT02726646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The application of 1 mg of microspheres placebo
Trial: NCT02605213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for control Group of primary sclerosing vhlangitis
Trial: NCT00860743
Drug: Antioxidant cocktail
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
Trial: NCT00141661
Drug: PF-04494700 - High Dose Arm
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg loading dose for 6 days, followed by 20 mg daily
Trial: NCT06193031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.
Trial: NCT00904748
Drug: Viagra®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
Trial: NCT01946984
Drug: Diclofenac hydroxyethylpyrrolidine
RxNorm normalized name: diclofenac hydroxyethylpyrrolidine 1.292 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no